Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 2/20 | 0.36 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.36 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15027784 | 0.96 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1LMNATLR2GAA | |
| SCHEMBL25989853 | 0.95 | ALDH1A1 (0.43) | ALDH1A1L3MBTL1PRKCAPRKCEPRKCQ | |
| SCHEMBL15027761 | 0.95 | ALDH1A1 (0.43) | ALDH1A1L3MBTL1PRKCAPRKCEPRKCQ | |
| SCHEMBL15148304 | 0.94 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1PRKCAPRKCEPRKCQ | |
| SCHEMBL15148273 | 0.93 | PRKCA (0.41) | ALDH1A1L3MBTL1PRKCAPRKCEPRKCQ | |
| SCHEMBL15027779 | 0.91 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1LMNATLR2GAA | |
| SCHEMBL15148243 | 0.90 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1PRKCAPRKCEPRKCQ | |
| SCHEMBL15148303 | 0.90 | ALDH1A1 (0.43) | ALDH1A1L3MBTL1PRKCAPRKCEPRKCQ | |
| SCHEMBL15148242 | 0.89 | PRKCA (0.41) | ALDH1A1L3MBTL1PRKCAPRKCEPRKCQ | |
| SCHEMBL15148318 | 0.87 | ALDH1A1 (0.37) | ALDH1A1L3MBTL1PRKCAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11071784-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20150273068-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2015-10-01 | — | — | US | disclosed |
| US-20150273068-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150273068-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | ALDH1A1 3151/4885L3MBTL1 1228/4885PRKCA 2786/4885 |
| US-11071784-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | ALDH1A1 3151/4885L3MBTL1 1228/4885PRKCA 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.